Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19931123 | 0.90 | BRD4 (0.52) | BRD4 | |
| SCHEMBL23473111 | 0.87 | BRD4 (0.49) | BRD4 | |
| SCHEMBL20384290 | 0.85 | BRD4 (0.77) | BRD4 | |
| SCHEMBL19930719 | 0.85 | BRD4 (0.51) | BRD4 | |
| SCHEMBL25042171 | 0.85 | BRD4 (0.52) | BRD4 | |
| SCHEMBL20155516 | 0.85 | BRD4 (0.52) | BRD4 | |
| SCHEMBL21648846 | 0.84 | BRD4 (0.55) | BRD4 | |
| SCHEMBL19931063 | 0.83 | BRD4 (0.49) | BRD4 | |
| SCHEMBL19931229 | 0.83 | BRD4 (0.49) | BRD4 | |
| SCHEMBL21915918 | 0.83 | BRD4 (0.52) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128975-A1 | PROCESS FOR THE PREPARATION OF BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| EP-4134364-A2 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| WO-2021262962-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | CELGENE CORPORATION (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021080950-A1 | METHODS FOR TREATING A HEMATOLOGICAL CANCER AND THE USE OF COMPANION BIOMARKERS FOR 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE | CELGENE CORPORATION (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021080955-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2020146440-A1 | ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING MULTIPLE MYELOMA | CELGENE CORPORATION (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020023438-A2 | PROCESS FOR THE PREPARATION OF BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2018075796-A1 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC (US) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128975-A1 | PROCESS FOR THE PREPARATION OF BROMODOMAIN INHIBITOR | BRD1, BRD4, BRD3 | BRD4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.